vTv Therapeutics Inc. (VTVT): Nasdaq/NYSE listing notice — vTv Therapeutics gets Nasdaq extension to Dec 2023; must reverse split by Nov 22

vTv Therapeutics Inc.

Nasdaq extended bid price compliance deadline to December 18, 2023.
Company must effect reverse stock split (1:10 to 1:20) by November 22, 2023.
Stockholder approval for reverse split required by October 30, 2023.
No assurance reverse split will ensure compliance; stock price impact uncertain.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

vTv Therapeutics Inc. received a nasdaq extension granted notice regarding minimum bid price.

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price

Exact text from the filing

July 17, 2023, the Company received notice from Nasdaq that, based upon the completed questionnaire and the expedited review process, it had approved the Company’s request to extend the period for the Company to regain compliance with the Minimum Bid Requirement until December 18, 2023. Nasdaq noted that the extension was based upon the Company’s representation that it would complete a reverse stock split no later than November 22, 2023, at a ratio between 1:10 and 1:20, and that it would obtain stockholder approval for such a reverse stock split on or before October 30, 2023. There can be no

View on SEC.gov

Browse all listing & compliance notices →

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001641489-23-000046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.